共 227 条
[1]
Denton CP(2017)Systemic sclerosis Lancet 390 1685-1699
[2]
Khanna D(2005)Classification of systemic sclerosis. Visions and reality Rheumatology (Oxford) 44 1212-1216
[3]
Wollheim FA(2012)Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies Rheumatology (Oxford) 51 1017-1026
[4]
Elhai M(2006)Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease N Engl J Med 354 2655-2666
[5]
Meune C(2016)Sclerodema Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial Lancet Respir Med 4 708-719
[6]
Avouac J(2015)EUSTAR Rituximab study group. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group Ann Rheum Dis 74 1188-1194
[7]
Kahan A(2017)A multicenter, open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease Arthritis Rheum 46 625-631
[8]
Allanore Y(2011)Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial Lancet 378 498-506
[9]
Tashkin DP(2014)Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial JAMA 311 2490-2498
[10]
Elashoff R(2018)SCOT Study Investigators. Myeloablative autologous stem-cell transplantation for severe scleroderma N Engl J Med 378 35-47